JP7629400B2 - エクテナサイジン誘導体を含む薬物抗体複合体 - Google Patents

エクテナサイジン誘導体を含む薬物抗体複合体 Download PDF

Info

Publication number
JP7629400B2
JP7629400B2 JP2021523064A JP2021523064A JP7629400B2 JP 7629400 B2 JP7629400 B2 JP 7629400B2 JP 2021523064 A JP2021523064 A JP 2021523064A JP 2021523064 A JP2021523064 A JP 2021523064A JP 7629400 B2 JP7629400 B2 JP 7629400B2
Authority
JP
Japan
Prior art keywords
group
substituted
unsubstituted
alkylene
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523064A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020084115A5 (https=
JP2022512830A5 (https=
JP2022512830A (ja
Inventor
マリア・デル・カルメン・クエバス・マルチャンテ
アンドレス・フランセシュ・ソロソ
アルフォンソ・ラトーレ・ロサノ
バレンティン・マルティネス・バラサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of JP2022512830A publication Critical patent/JP2022512830A/ja
Publication of JPWO2020084115A5 publication Critical patent/JPWO2020084115A5/ja
Publication of JP2022512830A5 publication Critical patent/JP2022512830A5/ja
Application granted granted Critical
Publication of JP7629400B2 publication Critical patent/JP7629400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021523064A 2018-10-25 2019-10-25 エクテナサイジン誘導体を含む薬物抗体複合体 Active JP7629400B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382759.1 2018-10-25
EP18382759 2018-10-25
PCT/EP2019/079188 WO2020084115A1 (en) 2018-10-25 2019-10-25 Antibody drug conjugates comprising ecteinascidin derivatives

Publications (4)

Publication Number Publication Date
JP2022512830A JP2022512830A (ja) 2022-02-07
JPWO2020084115A5 JPWO2020084115A5 (https=) 2024-03-21
JP2022512830A5 JP2022512830A5 (https=) 2024-03-21
JP7629400B2 true JP7629400B2 (ja) 2025-02-13

Family

ID=64426824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523064A Active JP7629400B2 (ja) 2018-10-25 2019-10-25 エクテナサイジン誘導体を含む薬物抗体複合体

Country Status (37)

Country Link
US (1) US20230012681A1 (https=)
EP (1) EP3870234B1 (https=)
JP (1) JP7629400B2 (https=)
KR (1) KR20210086669A (https=)
CN (1) CN113226377B (https=)
AR (1) AR117657A1 (https=)
AU (1) AU2019368687B2 (https=)
BR (1) BR112021007718A2 (https=)
CA (1) CA3117268C (https=)
CL (1) CL2021001039A1 (https=)
CO (1) CO2021006838A2 (https=)
DK (1) DK3870234T3 (https=)
EA (1) EA202191131A1 (https=)
EC (1) ECSP21035414A (https=)
ES (1) ES2939494T3 (https=)
FI (1) FI3870234T3 (https=)
HR (1) HRP20230275T1 (https=)
HU (1) HUE061606T2 (https=)
IL (1) IL282577B2 (https=)
JO (1) JOP20210083B1 (https=)
LT (1) LT3870234T (https=)
MA (1) MA59661B1 (https=)
MD (1) MD3870234T2 (https=)
MX (1) MX2021004746A (https=)
MY (1) MY206221A (https=)
PH (1) PH12021550930A1 (https=)
PL (1) PL3870234T3 (https=)
PT (1) PT3870234T (https=)
RS (1) RS64068B1 (https=)
SA (1) SA521421855B1 (https=)
SG (1) SG11202104154WA (https=)
SI (1) SI3870234T1 (https=)
SM (1) SMT202300076T1 (https=)
TW (1) TWI824043B (https=)
UA (1) UA129803C2 (https=)
WO (1) WO2020084115A1 (https=)
ZA (1) ZA202103478B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231233T1 (hr) * 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
TW202313039A (zh) * 2021-05-19 2023-04-01 西班牙商瑪製藥股份有限公司 Pm14用途與方案
KR102625740B1 (ko) * 2021-07-15 2024-01-17 주식회사 새한비엠 폐수지 재료 및 미네랄 바인더를 이용한 단열차음재의 제조 방법 및 그 단열차음재
CN120417935A (zh) * 2022-10-25 2025-08-01 默沙东有限责任公司 依喜替康衍生的adc接头-载荷及其药物组合物和用途
WO2024155565A2 (en) * 2023-01-17 2024-07-25 Yarrow Therapeutics, Inc. Ecteinascidin derivative antibody drug conjugates
WO2024186263A1 (en) 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
CN118878690B (zh) * 2023-11-28 2026-01-09 南京大学 一种抗地高辛纳米抗体的制备及其应用
WO2025228595A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
TW202547488A (zh) * 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 於癌症的治療中之化合物Ｉａ和拓樸異構酶Ｉ抑制劑的組合
WO2025233522A1 (en) * 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501093A (ja) 2001-08-07 2005-01-13 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍類似体
JP2013010773A (ja) 2004-08-26 2013-01-17 Satyam Apparao 新規バイオ開裂性リンカー

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
EP3539572A1 (en) 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
GB201506405D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
HRP20231233T1 (hr) * 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
KR20230004714A (ko) * 2020-04-21 2023-01-06 파르마 마르, 에스.에이. 약물 항체 접합체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501093A (ja) 2001-08-07 2005-01-13 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍類似体
JP2013010773A (ja) 2004-08-26 2013-01-17 Satyam Apparao 新規バイオ開裂性リンカー

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Annals of Oncology，2017年，Vol.28，pp.2559-2566
British Journal of Pharmacology，2010年，Vol.161，pp.1099-1110
Pharmaceuticals，2018年04月，Vol.11，Article No.32

Also Published As

Publication number Publication date
JOP20210083A1 (ar) 2023-01-30
CA3117268A1 (en) 2020-04-30
AR117657A1 (es) 2021-08-25
BR112021007718A2 (pt) 2021-08-10
HUE061606T2 (hu) 2023-07-28
SG11202104154WA (en) 2021-05-28
TW202034957A (zh) 2020-10-01
CL2021001039A1 (es) 2021-10-01
CO2021006838A2 (es) 2021-06-10
IL282577B2 (en) 2023-10-01
AU2019368687B2 (en) 2025-10-23
TWI824043B (zh) 2023-12-01
PL3870234T3 (pl) 2023-04-24
MY206221A (en) 2024-12-04
CN113226377B (zh) 2022-10-18
SMT202300076T1 (it) 2023-05-12
ES2939494T3 (es) 2023-04-24
IL282577A (en) 2021-06-30
AU2019368687A1 (en) 2021-06-10
MA59661B1 (fr) 2023-03-31
ZA202103478B (en) 2022-12-21
EP3870234B1 (en) 2022-12-21
DK3870234T3 (da) 2023-03-20
JOP20210083B1 (ar) 2024-12-22
EP3870234A1 (en) 2021-09-01
KR20210086669A (ko) 2021-07-08
US20230012681A1 (en) 2023-01-19
PT3870234T (pt) 2023-03-06
CA3117268C (en) 2023-11-21
MD3870234T2 (ro) 2023-05-31
CN113226377A (zh) 2021-08-06
FI3870234T3 (fi) 2023-03-23
RS64068B1 (sr) 2023-04-28
LT3870234T (lt) 2023-03-27
EA202191131A1 (ru) 2021-10-15
WO2020084115A1 (en) 2020-04-30
HRP20230275T1 (hr) 2023-04-28
IL282577B1 (en) 2023-06-01
SI3870234T1 (sl) 2023-06-30
SA521421855B1 (ar) 2023-12-11
MX2021004746A (es) 2021-08-24
JP2022512830A (ja) 2022-02-07
PH12021550930A1 (en) 2021-11-22
UA129803C2 (uk) 2025-08-06
ECSP21035414A (es) 2021-06-30

Similar Documents

Publication Publication Date Title
JP7629400B2 (ja) エクテナサイジン誘導体を含む薬物抗体複合体
ES2778045T3 (es) Conjugados fármaco-anticuerpo
JP7795475B2 (ja) 薬物抗体コンジュゲート
CN114615999B (zh) 药物抗体偶联物
HK40053316B (en) Antibody drug conjugates comprising ecteinascidin derivatives
HK40053316A (en) Antibody drug conjugates comprising ecteinascidin derivatives
EA046742B1 (ru) Конъюгаты антитело-лекарственное средство, содежащие производные эктеинасцидина
HK40067834B (en) Drug antibody conjugates
HK40067834A (en) Drug antibody conjugates
EA048715B1 (ru) Конъюгаты антитело-лекарственное средство

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20210614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231211

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250131

R150 Certificate of patent or registration of utility model

Ref document number: 7629400

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150